A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized treatments for myeloma patients. A research group in Singapore has used artificial intelligence (AI) to identify optimized combinatorial drug treatments for myeloma, a type of blood cancer. Their methods and findings are published in Science Translational Medicine....Continue Reading
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer (NCT02414269). Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 checkpoint inhibition treatment. Preliminary results from the...Continue Reading
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability and overcome patient’s ineffective immune surveillance. MRD analysis...Continue Reading
Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, the game-changing cancer treatment approved by the FDA for 2 indications, and being studied for more. The request for an NCD was put forth by UnitedHealthcare, the nation’s largest insurer and...Continue Reading
Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he’s ready for his experimental treatment. “How’s your night? Any issues?” asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid. Reid, 20, of Lucedale, Miss., has been fighting leukemia...Continue Reading
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more: https://www.biopharma-reporter.com/Article/2018/08/15/US-FDA-approves-first-non-gene-edited-allogeneic-CAR-T-cell-candidate-for-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyrightContinue Reading
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma (NDMM) compared with other regimens in the maintenance setting, according to a study published in JAMA Oncology.1 Many agents have demonstrated efficacy as maintenance agents in patients with NDMM. Due to a lack of comparative...Continue Reading
University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells. CAR-T therapy has been called a “living drug” and is part of a rapidly emerging immunotherapy approach called adoptive cell transfer (ACT), which collects...Continue Reading
Children treated with chimeric antigen receptor T-cell therapy experience unique toxicities that require careful monitoring to prevent serious sequalae, according to new management guidelines. An educated interdisciplinary team — including nurses, trainees, intensivists and cell therapists — is essential to identify early signs and symptoms of cytokine release syndrome (CRS) and chimeric antigen receptor (CAR)-T-cell-related...Continue Reading
